Phuturdex › Diseases › Myeloproliferative disorders
Drugs in development · updated 30 October 2026
Myeloproliferative disorders: drugs in development
As of 30 October 2026 there are 88 active clinical trials (recruiting or ongoing, phases I–III) on 91 drugs for myeloproliferative disorders. 25 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Itacitinib | II | 3 | NCT05364762 |
| Bezuclastinib TabletsCGT9486 | II | 1 | NCT04996875 |
| DISC-0974 | I–II | 1 | NCT05320198 |
| EmavusertibCA-4948 | II | 1 | NCT05564390 |
| Epetraborole | II | 1 | NCT07891533 |
| Iadademstat | II | 1 | NCT06661915 |
| JBI-802 | I–II | 1 | NCT07612280 |
| Monalizumab | II | 1 | NCT06892223 |
| OlverembatinibHQP1351 | II | 1 | NCT05521204 |
| ParsaclisibParsaclisib Incyte Biosciences Distribution B.V.® | II | 1 | NCT04509700 |
| Pevonedistat | I–II | 1 | NCT03862157 |
| INCA033989 | I | 2 | NCT05936359 |
| Navitoclax | I | 2 | NCT05455294 |
| CD34 | I | 1 | NCT05088356 |
| CK0804 | I | 1 | NCT05423691 |
| DMR-001 | I | 1 | NCT07849231 |
| INCA035784 | I | 1 | NCT07008118 |
| INCA036978 | I | 1 | NCT07441694 |
| INCB057643 | I | 1 | NCT04279847 |
| INCB160058 | I | 1 | NCT06313593 |
| LY3410738 | I | 1 | NCT04603001 |
| Onvansertib | I | 1 | NCT05549661 |
| PMD-026 | I | 1 | NCT07379125 |
| PRT12396 | I | 1 | NCT07469891 |
| Ropeginterferon | I | 1 | NCT07249840 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| RuxolitinibJakavi, Jakafi Xr® | III | 13 | NCT04562389 |
| CytarabineAra-C, Cytosine Arabinoside | III | 5 | NCT02521493 |
| LuspaterceptACE-536, Reblozyl | III | 4 | NCT04717414 |
| Ropeginterferon alfa-2bP1101, Besremi® | III | 4 | NCT06468033 |
| DaunorubicinDaunomycin, Daunoxome® | III | 3 | NCT02521493 |
| EtoposideAvopef®, Etopophos Preservative Free® | III | 2 | NCT02521493 |
| SelinexorKPT-330, Xpovio® | III | 2 | NCT04562389 |
| AnagrelideAgrylin®, Anagrelide Viatris (previously Anagrelide Mylan)® | III | 1 | NCT04285086 |
| AsciminibABL001, Scemblix® | III | 1 | NCT05456191 |
| Asparaginase Erwinia chrysanthemiL-asparaginase, Erwinia asparaginase | III | 1 | NCT02521493 |
| ImetelstatRytelo® | III | 1 | NCT04576156 |
| MitoxantroneNovantrone® | III | 1 | NCT02521493 |
| NilotinibDanziten®, Cavhanza® | III | 1 | NCT05456191 |
| Thioguanine | III | 1 | NCT02521493 |
| FludarabineFludara, FLUDARABIN | I–II | 17 | NCT03622788 |
Sorted by most advanced phase and number of active trials. Showing 15 of 66 drugs.
All 91 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Myelofibrosis 91 drugs
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive 68 drugs
- Acute myeloid leukemia 314 drugs
- Polycythemia vera 49 drugs
- Chronic phase chronic myelogenous leukemia 35 drugs
- Myelodysplastic Syndromes 203 drugs
- Precursor lymphoblastic lymphoma/leukemia 163 drugs
- Thrombocythemia, Essential 43 drugs
- Chronic myelomonocytic leukemia 90 drugs
- Non-Hodgkin lymphoma 269 drugs
- Accelerated phase chronic myelogenous leukemia 28 drugs
- Blast Crisis 32 drugs
Broader categories
- Bone marrow disease 14 drugs
- Hematologic Diseases 57 drugs
- Neoplasm 671 drugs
- Myeloid leukemia 26 drugs
- Leukemia 153 drugs
- Immune System Diseases 54 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D009196 “Myeloproliferative Disorders”.